Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous MAGE-C2-specific TCR T cells
- Development stage
- Unknown
- Lead developer
- Erasmus MC
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous MAGE-C2-specific TCR T cells is an investigational adoptive cell therapy developed by Erasmus University Medical Center (Erasmus MC). The therapy consists of a patient's own T cells that have been genetically modified to express a T-cell receptor (TCR) targeting the MAGE-C2 (MC2) cancer-germline antigen, specifically the ALK epitope presented by HLA-A2. MAGE-C2 is a tumor-selective antigen highly expressed in melanoma and head and neck squamous cell carcinoma (HNSCC) but absent in healthy adult tissues. The treatment protocol involves the administration of these engineered T cells following epigenetic modulation with azacitidine and valproic acid to enhance antigen expression, alongside low-dose interleukin-2 (IL-2) to support T-cell expansion and persistence. It is currently being evaluated in a Phase I/II clinical trial for patients with advanced melanoma or recurrent/metastatic HNSCC.
- Other names
- autologous MAGE-C2-specific TCR-engineered T cellsMAGE-C2 TCR T-cell therapyMAGE-C-2 TCR T-cell therapyMAGE-C 2 TCR T-cell therapy
02
Targets
MAGE-C2/HLA-A*02:01 (Melanoma-associated antigen C2 peptide–major histocompatibility complex)
Beyond the preview
Go deeper on autologous MAGE-C2-specific TCR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous MAGE-C2-specific TCR T cells.